{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:38:22Z","timestamp":1791833902322,"version":"4.3.4"},"reference-count":321,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000025","name":"NIMH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.psychres.2021.113853","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T15:14:22Z","timestamp":1614957262000},"page":"113853","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder"],"prefix":"10.1016","volume":"300","author":[{"given":"Christopher","family":"Pittenger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5468-6552","authenticated-orcid":false,"given":"Brian P.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorrin","family":"Koran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A.","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Nestadt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn I.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Blair","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1450-8051","authenticated-orcid":false,"given":"Petros","family":"Skapinakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan J.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2021.113853_bib0001","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/JCP.0b013e318192e9a4","article-title":"Memantine augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial","volume":"29","author":"Aboujaoude","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0002","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","article-title":"Exposure and response prevention in OCD","author":"Abramowitz","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0003","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1037\/a0018260","article-title":"Assessment of obsessive-compulsive symptom dimensions: Development and evaluation of the Dimensional Obsessive-Compulsive Scale","volume":"22","author":"Abramowitz","year":"2010","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.psychres.2021.113853_bib0004","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0005-7894(00)80045-3","article-title":"Does comorbid major depressive disorder influence outcome of exposure and response prevention for OCD?","volume":"31","author":"Abramowitz","year":"2000","journal-title":"Behav. Ther."},{"key":"10.1016\/j.psychres.2021.113853_bib0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.janxdis.2008.06.003","article-title":"Obsessive-compulsive symptoms: The contribution of obsessional beliefs and experiential avoidance","volume":"23","author":"Abramowitz","year":"2009","journal-title":"J. Anxiety. Disord."},{"key":"10.1016\/j.psychres.2021.113853_bib0006","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.cpr.2013.09.004","article-title":"The neuropsychology of adult obsessive-compulsive disorder: A meta-analysis","volume":"33","author":"Abramovitch","year":"2013","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.psychres.2021.113853_bib0007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eurpsy.2013.12.003","article-title":"Cigarette smoking in obsessive-compulsive disorder and unaffected parents of OCD patients","volume":"30","author":"Abramovitch","year":"2015","journal-title":"Eur. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0008","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Differentiating autism spectrum disorder and OCD","author":"Accordino","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004714-200206000-00012","article-title":"Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder","volume":"22","author":"Ackerman","year":"2002","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/JCP.0000000000000659","article-title":"Intranasal ketamine and cognitive-behavioral therapy for treatment-refractory obsessive-compulsive disorder","volume":"37","author":"Adams","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0011","article-title":"The role of stress in the pathogenesis and maintenance of obsessive-compulsive disorder","volume":"2","author":"Adams","year":"2018","journal-title":"Chronic. Stress. (Thousand Oaks)"},{"key":"10.1016\/j.psychres.2021.113853_bib0012","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/JCP.0b013e318272677d","article-title":"N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: A randomized, double-blind placebo-controlled trial","volume":"32","author":"Afshar","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0013","first-page":"19","article-title":"Treatment-resistant obsessive-compulsive disorder (OCD): Current knowledge and open questions","volume":"19","author":"Albert","year":"2013","journal-title":"Clin. Neuropsychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0014","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.4088\/JCP.v63n1108","article-title":"Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: A preliminary single-blind, 12-week, controlled study","volume":"63","author":"Albert","year":"2002","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0015","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2174\/1570159X16666180620155941","article-title":"Suicide risk in obsessive-compulsive disorder and exploration of risk factors: A systematic review","volume":"17","author":"Albert","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0133591","article-title":"Deep brain stimulation for obsessive-compulsive disorder: A meta-analysis of treatment outcome and predictors of response","volume":"10","author":"Alonso","year":"2015","journal-title":"PLoS. One."},{"issue":"suppl","key":"10.1016\/j.psychres.2021.113853_bib0017","first-page":"1","article-title":"Practice Guideline for the Treatment of Patients with Bipolar Disorder (revision)","volume":"159","author":"Association","year":"2002","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0018","series-title":"The Principles of Medical Ethics, With Annotations Especially Applicable to Psychiatry","year":"2013"},{"key":"10.1016\/j.psychres.2021.113853_bib0019","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.psychres.2021.113853_bib0020","series-title":"The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults","year":"2016"},{"key":"10.1016\/j.psychres.2021.113853_bib0021","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jad.2015.06.005","article-title":"The prevalence and predictors of comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review and meta-analysis","volume":"186","author":"Amerio","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.psychres.2021.113853_bib0022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajp.2016.01.009","article-title":"Course of illness in comorbid bipolar disorder and obsessive-compulsive disorder patients","volume":"20","author":"Amerio","year":"2016","journal-title":"Asian. J. Psychiatr."},{"key":"10.1016\/j.psychres.2021.113853_bib0023","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.4088\/JCP.14f09704","article-title":"Ondansetron augmentation of serotonin reuptake inhibitors as a treatment strategy in obsessive-compulsive disorder","volume":"76","author":"Andrade","year":"2015","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cpr.2015.03.002","article-title":"Suicidality in obsessive-compulsive disorder (OCD): A systematic review and meta-analysis","volume":"39","author":"Angelakis","year":"2015","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.psychres.2021.113853_bib0025","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in severe and long-term treatment-resistant obsessive-compulsive disorder","volume":"2013","author":"Arrojo-Romero","year":"2013","journal-title":"Case. Rep. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0026","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2165\/11635850-000000000-00000","article-title":"Granisetron adjunct to fluoxetine for moderate to severe obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial","volume":"26","author":"Askari","year":"2012","journal-title":"CNS. Drugs."},{"key":"10.1016\/j.psychres.2021.113853_bib0027","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamapsychiatry.2017.1567","article-title":"Inflammation in the neurocircuitry of obsessive-compulsive disorder","volume":"8","author":"Attwells","year":"2017","journal-title":"JAMA. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0028","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Mood and anxiety disorder comorbidity in OCD","author":"Baer","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0029","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/0972-6748.132930","article-title":"An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder","volume":"22","author":"Bakhla","year":"2013","journal-title":"Ind. Psychiatry. J."},{"key":"10.1016\/j.psychres.2021.113853_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/JCP.0000000000000989","article-title":"Effectiveness of venlafaxine in selective serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: Experience from a specialty clinic in India","volume":"39","author":"Balachander","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0031","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0032","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1080\/15622975.2016.1190867","article-title":"Biological markers for anxiety disorders, OCD, and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition","volume":"18","author":"Bandelow","year":"2017","journal-title":"World. J. Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0033","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.psychres.2021.113853_bib0034","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1176\/ajp.154.9.1293","article-title":"Addition of desipramine to serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder","volume":"154","author":"Barr","year":"1997","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/archpsyc.1987.01800150017003","article-title":"Local cerebral glucose metabolic rates in obsessive-compulsive disorder: A comparison with rates in unipolar depression and in normal controls","volume":"44","author":"Baxter","year":"1987","journal-title":"Arch. Gen. Psych."},{"key":"10.1016\/j.psychres.2021.113853_bib0036","doi-asserted-by":"crossref","first-page":"e331","DOI":"10.4088\/JCP.13r08672","article-title":"Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation","volume":"75","author":"Beach","year":"2014","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0037","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/08039480152036047","article-title":"Autistic traits in obsessive-compulsive disorder","volume":"55","author":"Bejerot","year":"2001","journal-title":"Nord. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0038","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","article-title":"Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Berlin","year":"2011","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0039","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0006-3223(00)00831-3","article-title":"The relationships of obsessive-compulsive disorder to possible spectrum disorders: results from a family study","volume":"48","author":"Bienvenu","year":"2000","journal-title":"Biol. Psychiatry."},{"issue":"1","key":"10.1016\/j.psychres.2021.113853_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033291711000742","article-title":"Is obsessive-compulsive disorder an anxiety disorder, and what, if any, are spectrum conditions? A family study perspective","volume":"42","author":"Bienvenu","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2021.113853_bib0041","first-page":"234","article-title":"A case of obsessive-compulsive disorder responding to duloxetine","volume":"9","author":"Blay","year":"2007","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0042","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004850-199603000-00005","article-title":"Sequential administration of augmentation strategies in treatment-resistant obsessive-compulsive disorder: Preliminary findings","volume":"11","author":"Blier","year":"1996","journal-title":"Int. J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0043","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Natural history and long-term outcome of OCD","author":"Bloch","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0044","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mp.2014.50","article-title":"Meta-analysis: hoarding associated with poor treatment outcome in obsessive-compulsive disorder","volume":"19","author":"Bloch","year":"2014","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0045","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/sj.mp.4001859","article-title":"A systematic review: Antipsychotic augmentation with treatment-refractory obsessive-compulsive disorder","volume":"11","author":"Bloch","year":"2006","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0046","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1176\/appi.ajp.2008.08020320","article-title":"Meta-analysis of the symptom structure of obsessive-compulsive disorder","volume":"165","author":"Bloch","year":"2008","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0047","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/ajmg.b.30699","article-title":"Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review","volume":"147B","author":"Bloch","year":"2008","journal-title":"Am. J. Med. Genet. B. Neuropsychiatr. Genet."},{"key":"10.1016\/j.psychres.2021.113853_bib0048","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRIs in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0049","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.biopsych.2012.05.028","article-title":"Effects of ketamine in treatment-refractory obsessive-compulsive disorder","volume":"72","author":"Bloch","year":"2012","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0050","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Quality of life and psychosocial functioning in OCD","author":"Boisseau","year":"2017"},{"issue":"3","key":"10.1016\/j.psychres.2021.113853_bib0051","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1139\/jpn.0527","article-title":"Comorbidity and pathophysiology of obsessive-compulsive disorder in schizophrenia: is there evidence for a schizo-obsessive subtype of schizophrenia?","volume":"30","author":"Bottas","year":"2005","journal-title":"J. Psychiatry. Neurosci."},{"key":"10.1016\/j.psychres.2021.113853_bib0052","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","article-title":"Commercial pharmacogenetic-based decision-support tools in psychiatry","volume":"3","author":"Bousman","year":"2016","journal-title":"Lancet. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0053","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12888-017-1230-5","article-title":"Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools","volume":"17","author":"Bousman","year":"2017","journal-title":"BMC. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jpsychires.2014.05.008","article-title":"Intensive residential treatment for severe obsessive-compulsive disorder: Characterizing treatment course and predictors of response","volume":"56","author":"Brennan","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0056","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Functional neuroimaging studies in obsessive-compulsive disorder: overview and synthesis","author":"Brennan","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0057","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.biopsych.2012.06.023","article-title":"A critical review of magnetic resonance spectroscopy studies of obsessive-compulsive disorder","volume":"73","author":"Brennan","year":"2013","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0058","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1192\/bjp.165.5.599","article-title":"Psychosurgery: Stereotactic subcaudate tractotomy. An indispensable treatment","volume":"165","author":"Bridges","year":"1994","journal-title":"Br. J. Psychiatry."},{"issue":"3","key":"10.1016\/j.psychres.2021.113853_bib0059","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.psc.2014.06.002","article-title":"Genetics of Obsessive-Compulsive Disorder and Related Disorders","volume":"37","author":"Browne","year":"2014","journal-title":"Psychiatr. Clin. N. Am."},{"issue":"4","key":"10.1016\/j.psychres.2021.113853_bib0060","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamapsychiatry.2014.2656","article-title":"Familial clustering of tic disorders and obsessive-compulsive disorder","volume":"72","author":"Browne","year":"2015","journal-title":"JAMA. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0061","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881111431751","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A double-blind, placebo-controlled study","volume":"26","author":"Bruno","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0062","series-title":"The Oxford Handbook of Obsessive Compulsive and Spectrum Disorders","article-title":"Phenomenology and epidemiology of obsessive compulsive disorder","author":"Calamari","year":"2012"},{"key":"10.1016\/j.psychres.2021.113853_bib0063","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0278-5846(00)00146-9","article-title":"On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder","volume":"25","author":"Carlsson","year":"2001","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"issue":"11","key":"10.1016\/j.psychres.2021.113853_bib0064","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1176\/appi.ajp.2019.18101180","article-title":"Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder: A prospective multicenter randomized double-blind placebo-controlled trial","volume":"176","author":"Carmi","year":"2019","journal-title":"Am J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0066","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cap.2014.0084","article-title":"Clinical evaluation of youth with pediatric acute-onset syndrome (PANS): Recommendations from the 2013 PANS Consensus Conference.","volume":"25","author":"Chang","year":"2015","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0067","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1080\/07420528.2019.1624563","article-title":"Circadian zeitgebers and treatment outcome in inpatient programs for obsessive compulsive disorder (OCD): A pilot study","volume":"36","author":"Coles","year":"2019","journal-title":"Chronobiol. Int."},{"key":"10.1016\/j.psychres.2021.113853_bib0069","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.biopsych.2005.04.043","article-title":"Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial","volume":"58","author":"Coric","year":"2005","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0070","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4088\/JCP.16m11101","article-title":"Randomized, double-blind, placebo-controlled trial of N-acetylcysteine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"78","author":"Costa","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2021.113853_bib0071","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamapsychiatry.2016.4287","article-title":"Efficacy of psychotherapies for borderline personality disorder: A systematic review and meta-analysis","volume":"74","author":"Cristea","year":"2017","journal-title":"JAMA. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0072","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0924-977X(00)00065-1","article-title":"Pidolol augmentation in treatment-resistant obsessive-compulsive disorder: A double-blind placebo-controlled trial","volume":"10","author":"Dannon","year":"2000","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0073","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003864","article-title":"Partitioning the heritability of Tourette syndrome and obsessive-compulsive disorder reveals differences in genetic architecture","volume":"9","author":"Davis","year":"2013","journal-title":"PLoS. Gen."},{"key":"10.1016\/j.psychres.2021.113853_bib0074","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0269881107079865","article-title":"Switching from serotonin reuptake inhibitors to duloxetine in patients with obsessive-compulsive disorder: A case series","volume":"22","author":"Dell'osso","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0075","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1017\/S1092852919001068","article-title":"Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive-compulsive disorder: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS)","volume":"25","author":"Dell'Osso","year":"2020","journal-title":"CNS Spectr"},{"key":"10.1016\/j.psychres.2021.113853_bib0076","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/j.euroneuro.2013.05.012","article-title":"Dopaminergic activity in Tourette syndrome and obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2013","journal-title":"Eur. Neuropsychopharm."},{"key":"10.1016\/j.psychres.2021.113853_bib0077","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/01.jcp.0000095342.32154.54","article-title":"A double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder","volume":"23","author":"Denys","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0078","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4088\/JCP.v65n0106","article-title":"A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder","volume":"65","author":"Denys","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2021.113853_bib0079","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1600-0447.1997.tb09929.x","article-title":"Prediction of outcome and early vs. late improvement in OCD patients treated with cognitive behavior therapy and pharmacotherapy","volume":"96","author":"de Haan","year":"1997","journal-title":"Acta. Psychiatr. Scand."},{"issue":"10","key":"10.1016\/j.psychres.2021.113853_bib0081","doi-asserted-by":"crossref","first-page":"e1240","DOI":"10.4088\/JCP.14m09736","article-title":"Tic-related versus tic-free obsessive-compulsive disorder: clinical picture and 2year natural course","volume":"77","author":"De Vries","year":"2016","journal-title":"J. Clin. Psychiatry."},{"issue":"2","key":"10.1016\/j.psychres.2021.113853_bib0082","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-014-0547-8","article-title":"Obsessive-compulsive personality disorder: A current review","volume":"17","author":"Diedrich","year":"2015","journal-title":"Curr. Psychiatry. Rep."},{"key":"10.1016\/j.psychres.2021.113853_bib0083","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/0269881108099423","article-title":"Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: A randomized, open-label trial","volume":"24","author":"Diniz","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.psychres.2021.113853_bib0084","doi-asserted-by":"crossref","first-page":"pyv047","DOI":"10.1093\/ijnp\/pyv047","article-title":"Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: An updated meta-analysis of double-blind, randomized, placebo-controlled trials","volume":"18","author":"Dold","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1176\/appi.ajp.159.2.269","article-title":"Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder","volume":"159","author":"Dougherty","year":"2002","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0086","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1007\/s00213-014-3516-3","article-title":"D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis","volume":"231","author":"Ducasse","year":"2014","journal-title":"Psychopharmacology. (Berl)."},{"key":"10.1016\/j.psychres.2021.113853_bib0087","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.comppsych.2003.09.010","article-title":"Insight in obsessive compulsive disorder and body dysmorphic disorder","volume":"45","author":"Eisen","year":"2004","journal-title":"Compr. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0088","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/pcn.12394","article-title":"Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study","volume":"70","author":"Emamzadehfard","year":"2016","journal-title":"Psychiatry. Clin. Neurosci."},{"key":"10.1016\/j.psychres.2021.113853_bib0089","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4088\/JCP.12m07789","article-title":"Treatment response, symptom remission, and wellness in obsessive-compulsive disorder","volume":"74","author":"Farris","year":"2013","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0090","unstructured":"FDA, 2012. FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide). https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm269086.htm."},{"key":"10.1016\/j.psychres.2021.113853_bib0091","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1038\/mp.2016.115","article-title":"Suicide in obsessive-compulsive disorder: a population-based study of 36788 Swedish patients","volume":"22","author":"Fernandez de la Cruz","year":"2017","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0092","first-page":"81","article-title":"Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: An open-label trial","volume":"42","author":"Feusner","year":"2009","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.psychres.2021.113853_bib0093","doi-asserted-by":"crossref","DOI":"10.1089\/cap.1998.8.61","article-title":"Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents","author":"Figueroa","year":"1998","journal-title":"J. Child Adolesc. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0094","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.psychres.2014.12.003","article-title":"Obsessive\u2013compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults","volume":"227","author":"Fineberg","year":"2015","journal-title":"Psychiatry. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0095","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/YIC.0000000000000314","article-title":"Clinical advances in obsessive-compulsive disorder: A position statement by the International College of Obsessive-Compulsive Spectrum Disorders","volume":"35","author":"Fineberg","year":"2020","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0096","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1037\/1040-3590.14.4.485","article-title":"The Obsessive-Compulsive Inventory: Development and validation of a short version","volume":"14","author":"Foa","year":"2002","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.psychres.2021.113853_bib0097","first-page":"90","article-title":"DSM-IV field trial: Obsessive-compulsive disorder","volume":"152","author":"Foa","year":"1995","journal-title":"Am. J. Psychiatry."},{"issue":"1","key":"10.1016\/j.psychres.2021.113853_bib0098","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","article-title":"Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder","volume":"162","author":"Foa","year":"2005","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0099","series-title":"Exposure and Response (Ritual) Prevention for Obsessive-Compulsive Disorder: Therapist Guide (Treatments That Work)","author":"Foa","year":"2012"},{"key":"10.1016\/j.psychres.2021.113853_bib0100","doi-asserted-by":"crossref","first-page":"949","DOI":"10.4088\/JCP.14r09129","article-title":"Electroconvulsive therapy for obsessive-compulsive disorder: A systematic review","volume":"76","author":"Fontenelle","year":"2015","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0101","doi-asserted-by":"crossref","first-page":"P65","DOI":"10.1016\/j.eclinm.2019.01.014","article-title":"A clinical staging model for obsessive-compulsive disorder: Is it ready for prime time?","volume":"7","author":"Fontenelle","year":"2019","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.psychres.2021.113853_bib0102","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.chc.2012.05.008","article-title":"Obsessive-compulsive and tic-related disorders","volume":"21","author":"Franklin","year":"2012","journal-title":"Child. Adolesc. Psychiatr. Clin. N. Am."},{"key":"10.1016\/j.psychres.2021.113853_bib0103","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.psychres.2015.02.009","article-title":"Cognitive-behavioral therapy for pediatric obsessive-compulsive disorder: Empirical review and clinical recommendations","volume":"227","author":"Franklin","year":"2015","journal-title":"Psychiatry. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0104","series-title":"Handbook of PTSD: Science and Practice","author":"Friedman","year":"2014"},{"issue":"1","key":"10.1016\/j.psychres.2021.113853_bib0105","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/01454455960201006","article-title":"Hoarding and obsessive-compulsive symptoms","volume":"20","author":"Frost","year":"1996","journal-title":"Behav. Modif."},{"key":"10.1016\/j.psychres.2021.113853_bib0106","series-title":"Psychodynamic Psychiatry in Clinical Practice","author":"Gabbard","year":"2005"},{"key":"10.1016\/j.psychres.2021.113853_bib0107","series-title":"Diagnosing Autism Spectrum Disorders: A Lifetime Perspective","author":"Gallo","year":"2010"},{"key":"10.1016\/j.psychres.2021.113853_bib0108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2014.07.009","article-title":"Factors associated with non-treatment or delayed treatment seeking in OCD sufferers: A review of the literature","volume":"220","author":"Garcia-Soriano","year":"2014","journal-title":"Psychiatry. Res."},{"issue":"1","key":"10.1016\/j.psychres.2021.113853_bib0109","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/da.20284","article-title":"Trauma and posttraumatic stress disorder in treatment-resistant obsessive-compulsive disorder","volume":"25","author":"Gershuny","year":"2018","journal-title":"Depress. Anxiety."},{"issue":"4","key":"10.1016\/j.psychres.2021.113853_bib0110","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0010-440X(95)90071-3","article-title":"Is there a relationship between clozapine and obsessive\u2013compulsive disorder? A retrospective chart review","volume":"36","author":"Ghaemi","year":"1995","journal-title":"Compr. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0111","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","article-title":"Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study","volume":"47","author":"Ghaleiha","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0113","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Habits and goals in OCD","author":"Gillan","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0114","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.biopsych.2009.11.028","article-title":"Deep brain stimulation for intractable obsessive-compulsive disorder: Pilot study using a blinded staggered-onset design","volume":"67","author":"Goodman","year":"2010","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0115","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","first-page":"517","article-title":"Deep brain stimulation for intractable OCD","author":"Goodman","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0116","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","article-title":"The Yale-Brown obsessive-compulsive scale. II","volume":"46","author":"Goodman","year":"1989","journal-title":"Validity. Arch. Gen. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0117","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown obsessive-compulsive scale. I. Development, use, and reliability. Arch","volume":"46","author":"Goodman","year":"1989","journal-title":"Gen. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0118","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Neurotransmitter dysregulation in obsessive-compulsive disorder","author":"Graat","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0119","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0006-3223(01)01074-5","article-title":"The familial phenotype of obsessive-compulsive disorder in relation to tic disorders: The Hopkins OCD Family Study","volume":"50","author":"Grados","year":"2001","journal-title":"Biol. Psychiatry."},{"issue":"5","key":"10.1016\/j.psychres.2021.113853_bib0120","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamapsychiatry.2016.0060","article-title":"N-acetylcysteine in the treatment of excoriation disorder: A randomized clinical trial","volume":"73","author":"Grant","year":"2016","journal-title":"JAMA Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0121","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jpsychires.2008.10.007","article-title":"Adjunctive glycine in the treatment of obsessive-compulsive disorder in adults","volume":"43","author":"Greenberg","year":"2009","journal-title":"J. Psyciahtr. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0122","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/npp.2009.128","article-title":"Invasive circuitry-based neurotherapeutics: stereotactic ablation and deep brain stimulation for obsessive-compulsive disorder","volume":"35","author":"Greenberg","year":"2010","journal-title":"Neuropsychopharm"},{"key":"10.1016\/j.psychres.2021.113853_bib0123","first-page":"243","article-title":"Cognitive inflexibility in obsessive-compulsive disorder","volume":"346","author":"Gruner","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.psychres.2021.113853_bib0124","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","first-page":"27","article-title":"Influence fo sex hormones on OCD","author":"Guglielmi","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0125","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","article-title":"Neurocircuitry underlying OCD: Neural networks underlying reward and action selection","author":"Haber","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0126","doi-asserted-by":"crossref","DOI":"10.1111\/acps.13276","article-title":"Deep brain stimulation versus ablative surgery for treatment-refractory obsessive-compulsive disorder: A meta-analysis","author":"Hageman","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.psychres.2021.113853_bib0127","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","article-title":"In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD)","volume":"229","author":"Haghighi","year":"2013","journal-title":"Psychopharmacology. (Berl)."},{"key":"10.1016\/j.psychres.2021.113853_bib0128","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","article-title":"Variable insight in OCD","author":"Hamblin","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0129","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/jpn.130055","article-title":"Escitalopram and QTc prolongation","volume":"38","author":"Hasnain","year":"2013","journal-title":"J. Psychiatry. Neurosci."},{"key":"10.1016\/j.psychres.2021.113853_bib0130","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/YIC.0000000000000043","article-title":"Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder","volume":"29","author":"Heidari","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0131","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: Advances in diagnosis and treatment","volume":"317","author":"Hirschtritt","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.psychres.2021.113853_bib0132","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archpsyc.57.1.76","article-title":"Multicenter double-blind comparison of sertraline and desipramien for concurrent obsessive-compulsive disorder and major depressive disorder","volume":"57","author":"Hoehn-Saric","year":"2000","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0133","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1192\/S0007125000297924","article-title":"Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study","volume":"35","author":"Hohagen","year":"1998","journal-title":"Br. J. Psychiatry. Suppl."},{"issue":"1","key":"10.1016\/j.psychres.2021.113853_bib0134","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.janxdis.2004.01.001","article-title":"The relationship between obsessive-compulsive and posttraumatic stress symptoms in clinical and non-clinical samples","volume":"19","author":"Huppert","year":"2005","journal-title":"J. Anxiety. Disord."},{"key":"10.1016\/j.psychres.2021.113853_bib0135","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4103\/0253-7176.155613","article-title":"Role of lamotrigine augmentation in treatment resistant obsessive-compulsive disorder: A retrospective case series review from South Asia","volume":"37","author":"Hussain","year":"2015","journal-title":"Indian. J. Psychol. Med."},{"key":"10.1016\/j.psychres.2021.113853_bib0136","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archpsyc.1983.04390010015002","article-title":"Obsessive-compulsive disorder: A double-blind trial of clomipramine and clorgyline","volume":"40","author":"Insel","year":"1983","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0137","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/mp.2017.154","article-title":"Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis","volume":"23","year":"2018","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0138","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005473.pub2","article-title":"Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders","author":"Ipser","year":"2006","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"10.1016\/j.psychres.2021.113853_bib0140","doi-asserted-by":"crossref","first-page":"e605","DOI":"10.4088\/JCP.14r09758","article-title":"Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder","volume":"77","author":"Issari","year":"2016","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0141","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.psychres.2015.01.015","article-title":"The place of and evidence for serotonin reuptake inhibitors (SRIs) for obsessive compulsive disorder (OCD) in children and adolescents: Views based on a systematic review and meta-analysis","volume":"227","author":"Ivarsson","year":"2015","journal-title":"Psychiatry. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0142","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1056\/NEJMcp031002","article-title":"Clinical practice: Obsessive-compulsive disorder","volume":"350","author":"Jenike","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.psychres.2021.113853_bib0143","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1176\/ajp.145.10.1285","article-title":"An open trial of buspirone in obsessive-compulsive disorder","volume":"145","author":"Jenike","year":"1988","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0144","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cne.22206","article-title":"Decreased number of parvalbumin and cholinergic interneurons in the striatum of individuals with Tourette syndrome","volume":"518","author":"Kataoka","year":"2010","journal-title":"J. Comp. Neurol."},{"issue":"Suppl 1","key":"10.1016\/j.psychres.2021.113853_bib0145","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","article-title":"Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress, and obsessive-compulsive disorders","volume":"14","author":"Katzman","year":"2014","journal-title":"BMC Psych"},{"key":"10.1016\/j.psychres.2021.113853_bib0146","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","article-title":"Functional neurosurgery in severe and treatment-refractory OCD","author":"Keen","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0147","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1192\/bjp.165.6.781","article-title":"Predictors of treatment outcome in the behavioural treatment of obsessive-compulsive disorder","volume":"165","author":"Keijsers","year":"1994","journal-title":"Br. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0148","first-page":"104","article-title":"Lamotrigine augmentation versus placebo in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A randomized controlled trial","volume":"11","author":"Khalkhali","year":"2016","journal-title":"Iran. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0149","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2176\/nmc.42.365","article-title":"Review of long-term results of stereotactic psychosurgery","volume":"42","author":"Kim","year":"2002","journal-title":"Neurol. Med. Chir. (Tokyo)."},{"key":"10.1016\/j.psychres.2021.113853_bib0150","series-title":"Handbook of Assessing Variants and Complications in Anxiety Disorders.","article-title":"Assessment of tics and comorbid obsessive-compulsive symptoms","author":"Kirkanski","year":"2013"},{"key":"10.1016\/j.psychres.2021.113853_bib0151","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4088\/JCP.v66n0312","article-title":"Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder","volume":"66","author":"Koran","year":"2005","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0152","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.4088\/JCP.08m04605","article-title":"Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder","volume":"70","author":"Koran","year":"2009","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0153","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4088\/JCP.v66n0415","article-title":"Mirtazapine for obsessive-compulsive disorder: An open trial followed by double-blind discontinuation","volume":"66","author":"Koran","year":"2005","journal-title":"J. Clin. Psychiatry."},{"issue":"7 suppl","key":"10.1016\/j.psychres.2021.113853_bib0154","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0155","series-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder.","author":"Koran","year":"2013"},{"key":"10.1016\/j.psychres.2021.113853_bib0156","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/j.1440-1614.2000.0751c.x","article-title":"Lamotrigine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder","volume":"34","author":"Kumar","year":"2000","journal-title":"Aust. N.Z. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0157","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/jnnp-2018-319318","article-title":"Comparative effectiveness of neuroablation and deep brain stimulation for treatment-resistant obsessive compulsive disorder: A meta-analytic study","volume":"90","author":"Kumar","year":"2019","journal-title":"J. Neurol. Neursurg. Psychiatry"},{"issue":"3","key":"10.1016\/j.psychres.2021.113853_bib0410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1016\/j.psychres.2021.113853_bib0158","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/archgenpsychiatry.2009.155","article-title":"Association of the glutamate transporter gene SLC1A1 with atypical antipsychotic-induced obsessive-compulsive symptoms","volume":"66","author":"Kwon","year":"2009","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0159","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00213-005-0246-6","article-title":"N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder","volume":"184","author":"Lafleur","year":"2006","journal-title":"Psychopharmacology. (Berl.)"},{"key":"10.1016\/j.psychres.2021.113853_bib0160","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1503\/jpn.120256","article-title":"Antidepressants and QTc prolongation","volume":"38","author":"Lam","year":"2013","journal-title":"J. Psychiatry. Neurosci."},{"key":"10.1016\/j.psychres.2021.113853_bib0161","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.biopsych.2014.03.026","article-title":"A randomized controlled trial of intranasal ketamine in major depressive disorder","volume":"76","author":"Lapidus","year":"2014","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0162","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/14737175.2016.1126181","article-title":"Family accommodation in obsessive-compulsive and anxiety disorders: a five-year update","volume":"16","author":"Lebowitz","year":"2016","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.psychres.2021.113853_bib0163","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/da.20669","article-title":"Obsessive-compulsive disorder: A review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V","volume":"27","author":"Leckman","year":"2010","journal-title":"Depress. Anxiety."},{"key":"10.1016\/j.psychres.2021.113853_bib0164","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamapsychiatry.2014.1193","article-title":"Gamma ventral capsulotomy for obsessive-compulsive disorder: A randomized clinical trial","volume":"71","author":"Lopes","year":"2014","journal-title":"JAMA. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0165","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0091270005280297","article-title":"Aging and clinical pharmacology: Implications for antidepressants","volume":"45","author":"Lotrich","year":"2005","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0166","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.comppsych.2011.06.008","article-title":"Skin picking and trichotillomania in adults with obsessive-compulsive disorder","volume":"53","author":"Lovato","year":"2012","journal-title":"Compr. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0167","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0278-5846(03)00039-3","article-title":"Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases","volume":"27","author":"Lykouras","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0168","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1017\/S0954579408000606","article-title":"The neural basis of obsessive-compulsive disorder in children and adults","volume":"20","author":"Maia","year":"2008","journal-title":"Dev. Psychopath."},{"key":"10.1016\/j.psychres.2021.113853_bib0169","first-page":"23","article-title":"Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: what if antipsychotic is discontinued?","volume":"18","author":"Maina","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0170","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa0708514","article-title":"Subthalamic nucleus stimulation in severe obsessive-compulsive disorder","volume":"359","author":"Mallet","year":"2008","journal-title":"New. Eng. J. Medicine."},{"key":"10.1016\/j.psychres.2021.113853_bib0171","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.janxdis.2008.08.008","article-title":"Substance use disorders in an obsessive-compulsive disorder clinical sample","volume":"23","author":"Mancebo","year":"2009","journal-title":"J. Anxiety. Disord."},{"key":"10.1016\/j.psychres.2021.113853_bib0172","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/YIC.0b013e32834cde39","article-title":"Plasma clomipramine levels in adult patients with obsessive-compulsive disorder","volume":"27","author":"Marazziti","year":"2012","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0173","doi-asserted-by":"crossref","first-page":"19r12821","DOI":"10.4088\/JCP.19r12821","article-title":"Efficacy, effect on mood symptoms, and safety of deep brain stimulation in refractory obsessive-compulsive disorder: A systematic review and meta-analysis","volume":"81","author":"Martinho","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2021.113853_bib0174","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-411546-0.00001-9","article-title":"An introduction to the clinical phenomenology of Tourette syndrome","volume":"112","author":"Martino","year":"2013","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.psychres.2021.113853_bib0175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/wps.20299","article-title":"Towards an international expert consensus for defining treatment response, remission, recovery and relapse in obsessive-compulsive disorder","volume":"15","author":"Mataix-Cols","year":"2016","journal-title":"World. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0176","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000064812","article-title":"Obsessive-compulsive symptom dimensions as predictors of compliance with and response to behavior therapy: Results from a controlled trial","volume":"71","author":"Mataix-Cols","year":"2002","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.psychres.2021.113853_bib0177","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/mp.2014.43","article-title":"Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS","volume":"20","author":"Mattheisen","year":"2015","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0178","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1176\/ajp.152.12.1812","article-title":"Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder","volume":"152","author":"McDougle","year":"1995","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0179","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1176\/ajp.150.4.647","article-title":"Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder","volume":"150","author":"McDougle","year":"1993","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0180","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00004714-199106000-00005","article-title":"A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: Lack of efficacy","volume":"11","author":"McDougle","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0181","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1017\/S1352465810000718","article-title":"OCD in the perinatal period: Is postpartum OCD (ppOCD) a distinct subtype? A review of the literature","volume":"39","author":"McGuinness","year":"2011","journal-title":"Behav. Cogn. Psychother."},{"key":"10.1016\/j.psychres.2021.113853_bib0182","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","article-title":"Clinical rating scales for OCD","author":"McGuire","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0183","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.comppsych.2011.03.002","article-title":"The role of avoidance in the phenomenology of obsessive-compulsive disorder","volume":"53","author":"McGuire","year":"2012","journal-title":"Compr. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0184","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.psychres.2015.02.004","article-title":"Efficacy of cognitive-behavioral therapy for obsessive-compulsive disorder.","volume":"227","author":"McKay","year":"2015","journal-title":"Psychiatry. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1362361304040636","article-title":"The broad autism phenotype: findings from an epidemiological survey","volume":"8","author":"Micali","year":"2004","journal-title":"Autism"},{"key":"10.1016\/j.psychres.2021.113853_bib0186","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.tics.2011.11.003","article-title":"Obsessive-compulsive disorder: Beyond segregated cortico-striatal pathways","volume":"16","author":"Milad","year":"2012","journal-title":"Trends. Cogn. Sci."},{"key":"10.1016\/j.psychres.2021.113853_bib0187","first-page":"1049","article-title":"Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease","volume":"50","author":"Montoya","year":"2002","journal-title":"Neurosurgery"},{"key":"10.1016\/j.psychres.2021.113853_bib0188","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0189","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1017\/S1092852912000065","article-title":"Topiramate augmentation in resistant OCD: A double-blind placebo-controlled clinical trial","volume":"15","author":"Mowla","year":"2010","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.psychres.2021.113853_bib0190","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.2174\/0929867324666171108145127","article-title":"Obsessive-compulsive disorder with comorbid bipolar disorders: Clinical features and treatment implications","volume":"25","author":"Mucci","year":"2018","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.psychres.2021.113853_bib0191","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/00004850-199809000-00005","article-title":"Effect of adjuvant pindolol on the anti-obsessional response to fluvoxamine: A double-blind, placebo-controlled study","volume":"13","author":"Mundo","year":"1998","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0193","series-title":"Obsessive-compulsive disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. National Practice Guideline Number 31","year":"2006"},{"key":"10.1016\/j.psychres.2021.113853_bib0195","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1017\/S0033291701003579","article-title":"The relationship between obsessive-compulsive disorder and anxiety and affective disorders: results from the Johns Hopkins OCD Family Study","volume":"31","author":"Nestadt","year":"2001","journal-title":"Psychol. Med."},{"key":"10.1016\/j.psychres.2021.113853_bib0196","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1177\/0269881113486718","article-title":"Two cases of delayed-onset suicidal ideation, dysphoria, and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder","volume":"27","author":"Niciu","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0197","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41467-017-00831-x","article-title":"Integrating evolutionary and regulatory information with multispecies approach implicates genes and pathways in obsessive-compulsive disorder","volume":"8","author":"Noh","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.psychres.2021.113853_bib0198","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1745-6924.2008.00088.x","article-title":"Rethinking rumination","volume":"3","author":"Nolen-Hoeksema","year":"2008","journal-title":"Perspect. Psychol. Sci."},{"key":"10.1016\/j.psychres.2021.113853_bib0199","series-title":"Post-Traumatic Stress Disorder: Diagnosis, Management, and Treatment","author":"Nutt","year":"2000"},{"key":"10.1016\/j.psychres.2021.113853_bib0200","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0005-7967(02)00099-2","article-title":"Psychometric validation of the Obsessive Beliefs Questionnaire and the Interpretation of Intrusions Inventory. Part I","volume":"41","year":"2003","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.psychres.2021.113853_bib0201","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.brat.2004.07.010","article-title":"Psychometric validation of the Obsessive Beliefs Questionnaire and the Interpretation of Intrusions Inventory. Part 2: Factor analyses and testing of a brief version","volume":"43","year":"2005","journal-title":"Behav. Res. Ther."},{"issue":"3","key":"10.1016\/j.psychres.2021.113853_bib0202","doi-asserted-by":"crossref","first-page":"50","DOI":"10.5498\/wjp.v3.i3.50","article-title":"Differential diagnosis of obsessive-compulsive symptoms from delusions in schizophrenia: A phenomenological approach","volume":"3","author":"Oulis","year":"2013","journal-title":"World. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0203","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Incompleteness and harm avoidance in OCD","author":"Pallanti","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0204","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2165\/11530240-000000000-00000","article-title":"Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: A preliminary, single-blind, retrospective study","volume":"23","author":"Pallanti","year":"2009","journal-title":"CNS. Drugs."},{"key":"10.1016\/j.psychres.2021.113853_bib0205","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.euroneuro.2013.12.003","article-title":"Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: Improvement with treatment and worsening following discontinuation","volume":"24","author":"Pallanti","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0206","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.4088\/JCP.v65n1015","article-title":"Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study","volume":"65","author":"Pallanti","year":"2004","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0207","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0924-9338(99)80725-1","article-title":"Citalopram for treatment-resistant obsessive-compulsive disorder","volume":"14","author":"Pallanti","year":"1999","journal-title":"Eur. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0208","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.pnpbp.2006.04.013","article-title":"Memantine augmentation for refractory obsessive-compulsive disorder","volume":"30","author":"Pasquini","year":"2006","journal-title":"Prog. Neuropsychopharm. Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0209","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.4088\/JCP.09m05537blu","article-title":"Patient preferences for obsessive-compulsive disorder treatment","volume":"71","author":"Patel","year":"2010","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0210","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.smrv.2012.12.002","article-title":"Sleep and obsessive-compulsive disorder (OCD)","volume":"17","author":"Paterson","year":"2013","journal-title":"Sleep. Med. Rev."},{"key":"10.1016\/j.psychres.2021.113853_bib0211","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.rpsmen.2012.07.006","article-title":"Differential diagnosis between obsessive compulsive disorder and restrictive and repetitive behavioural patterns, activities, and interests in autism spectrum disorders","volume":"6","author":"Paula-P\u00e9rez","year":"2013","journal-title":"Rev. Psicuiatr. Salud. Ment. (English Edition)"},{"key":"10.1016\/j.psychres.2021.113853_bib0212","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nrn3746","article-title":"Obsessive-compulsive disorder: An integrative genetic and neurobiological perspective","volume":"15","author":"Pauls","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.psychres.2021.113853_bib0213","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/jcpt.12370","article-title":"N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: Randomized, double-blind, placebo-cotrolled trial","volume":"41","author":"Paydary","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.psychres.2021.113853_bib0214","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjp.bp.113.137018","article-title":"Anti-basal ganglia antibodies in primary obsessive-compulsive disorder: Systematic review and meta-analysis","volume":"204","author":"Pearlman","year":"2014","journal-title":"Br. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0215","series-title":"Obsessive-Compulsive Disorders: A Complete Guide to Getting Well and Staying Well","author":"Penzel","year":"2016"},{"key":"10.1016\/j.psychres.2021.113853_bib0216","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Clinical presentation of OCD","author":"Penzel","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0217","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3171\/2014.11.JNS132618","article-title":"Deep brain stimulation versus anterior capsulotomy for obsessive-compulsive disorder: A review of the literature","volume":"122","author":"Pepper","year":"2015","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.psychres.2021.113853_bib0218","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.brat.2010.07.003","article-title":"When hoarding is a symptom of OCD: A case series and implications for DSM-V","volume":"48","author":"Pertusa","year":"2010","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.psychres.2021.113853_bib0219","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jpsychires.2012.05.016","article-title":"A comparison of insight in body dysmorphic disorder and obsessive-compulsive disorder","volume":"46","author":"Phillips","year":"2012","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0220","series-title":"Handbook on Obsessive-Compulsive and Related Disorders","author":"Phillips","year":"2015"},{"key":"10.1016\/j.psychres.2021.113853_bib0340","doi-asserted-by":"crossref","first-page":"113854","DOI":"10.1016\/j.psychres.2021.113854","article-title":"Knowledge and competency standards for specialized cognitive behavior therapy for pediatric obsessive-compulsive disorder","volume":"299","author":"Piacentini","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0221","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00004714-199202000-00003","article-title":"A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder","volume":"12","author":"Pigott","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0222","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4088\/JCP.v67n0503","article-title":"The Brown Longitudinal Obsessive Compulsive Study: Clinical Features and symptoms of the sample at intake","volume":"67","author":"Pinto","year":"2006","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0223","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00004714-199108000-00004","article-title":"A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine treated patients with obsessive-compulsive disorder","volume":"11","author":"Pigott","year":"1991","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0224","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3928\/00485713-20150602-06","article-title":"Glutamate modulators in the treatment of obsessive-compulsive disorder","volume":"45","author":"Pittenger","year":"2015","journal-title":"Psychiatr. Ann."},{"key":"10.1016\/j.psychres.2021.113853_bib0225","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/164_2016_127","article-title":"Histidine decarboxylase knockout mice as a model of the pathophysiology of Tourette syndrome and related conditions","volume":"241","author":"Pittenger","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0226","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","article-title":"The pharmacological treatment of refractory OCD","author":"Pittenger","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0227","series-title":"Current Topics in Behavioral Neurosciences: Future Trends in Obsessive-Compulsive and Related Disorders Research.","doi-asserted-by":"crossref","DOI":"10.1007\/7854_2020_204","article-title":"Pharmacotherapeutic strategies and new targets in OCD","author":"Pittenger","year":"2021"},{"key":"10.1016\/j.psychres.2021.113853_bib0228","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.psc.2014.05.006","article-title":"Pharmacological treatment of obsessive-compulsive disorder","volume":"37","author":"Pittenger","year":"2014","journal-title":"Psychiatr. Clin. North. Am."},{"key":"10.1016\/j.psychres.2021.113853_bib0229","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.pharmthera.2011.09.006","article-title":"Glutamate abnormalities in obsessive-compulsive disorder: Neurobiology, pathophysiology, and treatment","volume":"132","author":"Pittenger","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.psychres.2021.113853_bib0230","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.14m09123","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: A pilot randomized placebo-controlled trial","volume":"76","author":"Pittenger","year":"2015","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0231","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/JCP.0b013e3181727548","article-title":"Riluzole augmentation in treatment-refractory obsessive-compulsive disorder","volume":"28","author":"Pittenger","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0232","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1517\/14656566.2014.914493","article-title":"An updated review of antidepressants with marked serotonergic effects in obsessive-compulsive disorder","volume":"15","author":"Pizarro","year":"2014","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.psychres.2021.113853_bib0233","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/01.jcp.0000162809.69323.66","article-title":"The pharmacokinetic imperative in late-life depression","volume":"25","author":"Pollock","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.psychres.2021.113853_bib0234","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900004570","article-title":"A profile of obsessive-compulsive symptoms in schizophrenia","volume":"2","author":"Porto","year":"1997","journal-title":"CNS. Spectr."},{"key":"10.1016\/j.psychres.2021.113853_bib0235","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Obsessive-compulsive symptoms in schizophrenia: Clinical features, neurobiological correlates, and treatment","author":"Poyurovsky","year":"2017"},{"issue":"4","key":"10.1016\/j.psychres.2021.113853_bib0236","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jpsychires.2004.09.004","article-title":"Obsessive-compulsive disorder (OCD) with schizotypy versus schizophrenia with OCD: diagnostic dilemmas and therapeutic implications","volume":"39","author":"Poyurovsky","year":"2005","journal-title":"J. Psychiatr. Res."},{"issue":"14","key":"10.1016\/j.psychres.2021.113853_bib0237","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2165\/00023210-200418140-00004","article-title":"Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment","volume":"18","author":"Poyurovsky","year":"2004","journal-title":"CNS. Drugs."},{"key":"10.1016\/j.psychres.2021.113853_bib0238","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1176\/appi.ajp.162.11.2191-a","article-title":"Memantine for treatment-resistant OCD","volume":"162","author":"Poyurovsky","year":"2005","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0239","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/mp.2015.32","article-title":"Whole-genome association analysis of treatment response in obsessive-compulsive disorder","volume":"21","author":"Qin","year":"2016","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0240","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.comppsych.2010.09.006","article-title":"Comorbid major depression in obsessive-compulsive disorder patients","volume":"52","author":"Quarantini","year":"2011","journal-title":"Compr. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0241","first-page":"205","article-title":"Glutamate genetics in obsessive-compulsive disorder: A review","volume":"26","author":"Rajendram","year":"2017","journal-title":"J. Can. Acad. Child. Adolesc. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0242","doi-asserted-by":"crossref","DOI":"10.2174\/1570159X17666190409142555","article-title":"Brain stimulation in obsessive-compulsive disorder: A systematic review","author":"Rapinesi","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0243","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.biopsych.2017.11.034","article-title":"Gamma ventral capsulotomy in intractable obsessive-compulsive disorder","volume":"84","author":"Rasmussen","year":"2018","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0244","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.1994.03950010062008","article-title":"Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography","volume":"51","author":"Rauch","year":"1994","journal-title":"Arch. Gen. Psych."},{"key":"10.1016\/j.psychres.2021.113853_bib0245","article-title":"Drug treatment of obsessive-compulsive disorder (OCD): Long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs)","volume":"32","author":"Ravizza","year":"1996","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.psychres.2021.113853_bib0246","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/da.22672","article-title":"How willing are you? Willingness as a predictor of change during treatment of adults with obsessive-compulsive disorder","volume":"34","author":"Reid","year":"2017","journal-title":"Depress. Anxiety."},{"key":"10.1016\/j.psychres.2021.113853_bib0247","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4088\/JCP.10l06653","article-title":"Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder","volume":"72","author":"Rodriguez","year":"2011","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0248","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1038\/npp.2013.150","article-title":"Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept","volume":"38","author":"Rodriguez","year":"2013","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.psychres.2021.113853_bib0249","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4088\/JCP.16cr11234","article-title":"Challenges in testing intranasal ketamine in obsessive-compulsive disorder","volume":"78","author":"Rodriguez","year":"2017","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0250","doi-asserted-by":"crossref","first-page":"408","DOI":"10.4088\/JCP.15l10138","article-title":"Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial","volume":"77","author":"Rodriguez","year":"2016","journal-title":"J. Clin. Psychiatry."},{"issue":"1","key":"10.1016\/j.psychres.2021.113853_bib0251","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ajmg.b.30149","article-title":"A family study of early-onset obsessive-compulsive disorder","volume":"136B","author":"Rosario-Campos","year":"2005","journal-title":"Am. J. Med. Genet. B. Neuropsychiatr. Genet."},{"key":"10.1016\/j.psychres.2021.113853_bib0252","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.neuroscience.2009.10.043","article-title":"The glutamate-based genetic immune hypothesis in obsessive-compulsive disorder: An integrative approach from genes to symptoms","volume":"165","author":"Rotge","year":"2010","journal-title":"Neurosci."},{"key":"10.1016\/j.psychres.2021.113853_bib0253","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.jcp.0000220524.44905.9f","article-title":"The effects of topiramate adjunctive treatment added to antidepressants in patients with resistant obsessive-compulsive disorder","volume":"26","author":"Rubio","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0254","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0255","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0005-7967(01)00026-2","article-title":"Hoarding in obsessive compulsive disorder: results from a case-control study","volume":"40","author":"Samuels","year":"2002","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.psychres.2021.113853_bib0256","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamapsychiatry.2017.0080","article-title":"American Psychiatric Association Council of Research Task Force on Novel Biomarkers and Treatments. A consensus statement on the use of ketamine in the treatment of mood disorders","volume":"74","author":"Sanacora","year":"2017","journal-title":"JAMA. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0257","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","article-title":"N-acetylcysteine (NAC) in the treatment of obsessive-compulsive disorder: A 16-week, double-blind, randomized, placebo-controlled study","volume":"29","author":"Sarris","year":"2015","journal-title":"CNS. Drugs."},{"key":"10.1016\/j.psychres.2021.113853_bib0258","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/archpsyc.59.3.250","article-title":"Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs. major depression","volume":"59","author":"Saxena","year":"2002","journal-title":"Arch. Gen. Psych."},{"key":"10.1016\/j.psychres.2021.113853_bib0259","series-title":"Obsessive-compulsive Symptoms in Schizophrenia","article-title":"Epidemiology: prevalence and clinical characteristics of obsessive-compulsive symptoms in patients with psychotic disorders","author":"Schirmbeck","year":"2015"},{"key":"10.1016\/j.psychres.2021.113853_bib0260","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/hup.2461","article-title":"Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of the literature","volume":"30","author":"Serata","year":"2015","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0261","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/(SICI)1520-6394(1997)6:4<170::AID-DA7>3.0.CO;2-G","article-title":"Open-label pilot study of tramadol hydrochloride in treatment-refractory obsessive-compulsive disorder","volume":"6","author":"Shapira","year":"1997","journal-title":"Depress. Anxiety."},{"key":"10.1016\/j.psychres.2021.113853_bib0262","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0006-3223(03)00003-9","article-title":"Brain activation by disgust-inducing pictures in obsessive-compulsive disorder","volume":"54","author":"Shapira","year":"2003","journal-title":"Biol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0263","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jpsychires.2014.06.010","article-title":"Phenomenology of OCD: Lessons from a large multicenter study and implications for ICD-11","volume":"57","author":"Shavitt","year":"2014","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0264","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3171\/2012.11.JNS12389","article-title":"Limbic system surgery for treatment-refractory obsessive-compulsive disorder: A prospective long-term follow-up of 64 patients","volume":"118","author":"Sheth","year":"2013","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.psychres.2021.113853_bib0265","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1017\/S0033291713001803","article-title":"Cognitive functioning in obsessive-compulsive disorder: A meta-analysis","volume":"44","author":"Shin","year":"2014","journal-title":"Psychol. Med."},{"issue":"8","key":"10.1016\/j.psychres.2021.113853_bib0266","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1176\/ajp.152.8.1207","article-title":"Body dysmorphic disorder in the DSM-IV field trial for obsessive-compulsive disorder","volume":"152","author":"Simeon","year":"1995","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0267","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","first-page":"36","article-title":"Overview of the treatment of OCD","author":"Simpson","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0268","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamapsychiatry.2013.1932","article-title":"Cognitive-behavioral therapy vs. risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: A randomized clinical trial","volume":"70","author":"Simpson","year":"2013","journal-title":"JAMA. Psychiatry."},{"issue":"5","key":"10.1016\/j.psychres.2021.113853_bib0269","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1176\/appi.ajp.2007.07091440","article-title":"A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder","volume":"165","author":"Simpson","year":"2008","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0270","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.4088\/JCP.12l07879","article-title":"Patient adherence to cognitive-behavioral therapy predicts long-term outcome in obsessive-compulsive disorder","volume":"73","author":"Simpson","year":"2012","journal-title":"J. Clin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0271","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/npp.2012.132","article-title":"Investigation of cortical glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder by proton magnetic resonance spectroscopy","volume":"37","author":"Simpson","year":"2012","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.psychres.2021.113853_bib0272","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S2215-0366(16)30069-4","article-title":"Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: A systematic review and network meta-analysis","volume":"3","author":"Skapinakis","year":"2016","journal-title":"Lancet. Psychiatry."},{"issue":"43","key":"10.1016\/j.psychres.2021.113853_bib0273","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta20430","article-title":"A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive in children\/adolescents and adults","volume":"20","author":"Skapinakis","year":"2016","journal-title":"Health. Technol. Assess."},{"key":"10.1016\/j.psychres.2021.113853_bib0275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/2167702614534210","article-title":"Obsessive-compulsive disorder is associated with broad impairments in executive function: A meta-analysis","volume":"3","author":"Snyder","year":"2015","journal-title":"Clin. Psychol. Sci."},{"key":"10.1016\/j.psychres.2021.113853_bib0276","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/hup.1145","article-title":"A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder","volume":"25","author":"Soltani","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0277","doi-asserted-by":"crossref","first-page":"113753","DOI":"10.1016\/j.psychres.2021.113753","volume":"298","author":"Sookman","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0278","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113752","article-title":"Knowledge and competency standards for specialized cognitive behavior therapy for adult obsessive-compulsive disorder","volume":"303","author":"Sookman","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0279","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.psychres.2014.12.002","article-title":"Specialized psychological and pharmacological treatments for obsessive-compulsive disorder throughout the lifespan: a special series by the Accreditation Task Force (ATF) of the Canadian Institute for Obsessive Compulsive Disorders (CIOCD, www. ciocd. ca)","volume":"227","author":"Sookman","year":"2015","journal-title":"Psychiatry. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0280","article-title":"Obsessive-compulsive disorder","volume":"2012","author":"Soomro","year":"2012","journal-title":"BMJ. Clin. Evid."},{"key":"10.1016\/j.psychres.2021.113853_bib0281","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001765.pub3","article-title":"Selective serotonin reuptake inhibitors (SSRIs) versus placebo for obsessive-compulsive disorder","author":"Soomro","year":"2008","journal-title":"Cochrane. Database. Syst. Rev."},{"key":"10.1016\/j.psychres.2021.113853_bib0282","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/YCO.0000000000000291","article-title":"Current understanding of the relationship between obsessive-compulsive disorder and personality disturbance","volume":"30","author":"Starcevic","year":"2017","journal-title":"Curr. Opin. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0283","series-title":"Depressive Disorders","article-title":"Diagnosis of depressive disorders","author":"Stefanis","year":"2002"},{"key":"10.1016\/j.psychres.2021.113853_bib0284","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-019-0102-3","volume":"5","author":"Stein","year":"2019","journal-title":"Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.psychres.2021.113853_bib0285","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/comp.2001.19746","article-title":"Effects of Axis I and Axis II comorbidity on behavior therapy outcome for obsessive-compulsive disorder and agoraphobia","volume":"42","author":"Steketee","year":"2001","journal-title":"Compr. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0286","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","article-title":"A single-blinded case-control study of memantine in severe obsessive-compulsive disorder","volume":"30","author":"Stewart","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0287","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1176\/foc.8.3.foc350","article-title":"Clinical synthesis: The genetics of obsessive-compulsive disorder","volume":"8","author":"Stewart","year":"2010","journal-title":"FOCUS"},{"key":"10.1016\/j.psychres.2021.113853_bib0288","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","article-title":"Treatment of pediatric OCD","author":"Stewart","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0289","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jpsychires.2005.01.004","article-title":"Effectiveness of intensive residential treatment (IRT) for severe, refractory obsessive-compulsive disorder","volume":"39","author":"Stewart","year":"2005","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2021.113853_bib0290","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1037\/a0018492","article-title":"Development and psychometric evaluation of the Yale-Brown obsessive-compulsive scale \u2013 second edition","volume":"22","author":"Storch","year":"2010","journal-title":"Psychol. Assess."},{"key":"10.1016\/j.psychres.2021.113853_bib0291","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jocrd.2014.01.003","article-title":"Examining an obsessive-compulsive core dimensions model: Structural validity of harm avoidance and incompleteness","volume":"3","author":"Summerfeldt","year":"2014","journal-title":"J. Obsessive. Compuls. Relat. Disord."},{"key":"10.1016\/j.psychres.2021.113853_bib0292","first-page":"13","article-title":"From research subgroup to clinical syndrome: Modifying the PANDAS criteria to define PANS (pediatric acute-onset neuropsychiatric syndrome)","volume":"25","author":"Swedo","year":"2012","journal-title":"Pediatr. Therapeut."},{"key":"10.1016\/j.psychres.2021.113853_bib0331","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"PANDAS as a poststreptococcal autoimmune form of OCD","author":"Swedo","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0294","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/mp.2012.76","article-title":"Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies","volume":"18","author":"Taylor","year":"2013","journal-title":"Mol. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0295","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ajmg.b.32407","article-title":"Disorder-specific genetic factors in obsessive-compulsive disorder: A comprehensive meta-analysis","volume":"171B","author":"Taylor","year":"2016","journal-title":"Am. J. Med. Genet. B. Neuropsychiatr. Genet."},{"key":"10.1016\/j.psychres.2021.113853_bib0296","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1521\/pedi_2013_27_104","article-title":"The effect of personality disorders on treatment outcomes in patients with obsessive-compulsive disorders","volume":"27","author":"Thiel","year":"2013","journal-title":"J. Pers. Disord."},{"key":"10.1016\/j.psychres.2021.113853_bib0297","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1875397300802010062","article-title":"Glutamatergic synaptic dysfunction and obsessive-compulsive disorder","volume":"2","author":"Ting","year":"2008","journal-title":"Curr. Chem. Genomics."},{"issue":"1","key":"10.1016\/j.psychres.2021.113853_bib0298","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00127-015-1104-4","article-title":"Prevalence of substance use disorders in psychiatric patients: a nationwide Danish population-based study","volume":"51","author":"Toftdahl","year":"2016","journal-title":"Soc. Psychiatry. Psychiatr. Epidemiol."},{"key":"10.1016\/j.psychres.2021.113853_bib0299","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/archneur.1993.00540100012008","article-title":"Definitions and classification of tic disorders","volume":"50","year":"1993","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.psychres.2021.113853_bib0300","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/YCT.0000000000000335","article-title":"Transcranial magnetic stimulation for obsessive-compulsive disorder: An updated systematic review and meta-analysis","volume":"32","author":"Trevizol","year":"2016","journal-title":"J. ECT."},{"key":"10.1016\/j.psychres.2021.113853_bib0301","unstructured":"U.S. Food and Drug Administration (FDA) Web-site, 2012: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm269086.htm accessed 01\/09\/2015."},{"key":"10.1016\/j.psychres.2021.113853_bib0302","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1177\/0269881108098809","article-title":"Lamotrigine as an augmentation agent in treatment-resistant obsessive-compulsive disorder: A case report","volume":"24","author":"Uzun","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0303","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20118","article-title":"Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: A retrospective open-label case series","volume":"23","author":"Van Ameringen","year":"2006","journal-title":"Depress. Anxiety."},{"key":"10.1016\/j.psychres.2021.113853_bib0304","doi-asserted-by":"crossref","first-page":"E31","DOI":"10.1503\/jpn.150100","article-title":"Topiramate augmentation in a patient with obsessive-compulsive disorder","volume":"40","author":"Van Ameringen","year":"2015","journal-title":"J. Psychiatry. Neurosci."},{"key":"10.1016\/j.psychres.2021.113853_bib0305","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.euroneuro.2015.12.005","article-title":"Brain circuitry of compulsivity.","volume":"26","author":"Van den Heuvel","year":"2015","journal-title":"Eur. Neuropsychopharm"},{"key":"10.1016\/j.psychres.2021.113853_bib0306","doi-asserted-by":"crossref","first-page":"17464","DOI":"10.1038\/s41598-017-17593-7","article-title":"Impact of treatment on resting cerebral blood flow and metabolism in obsessive-compulsive disorder","volume":"7","author":"van der Straten","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.psychres.2021.113853_bib0307","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1375\/twin.8.5.450","article-title":"Twin studies on obsessive-compulsive disorder: a review","volume":"8","author":"van Grootheest","year":"2005","journal-title":"Twin. Res. Hum. Genet."},{"key":"10.1016\/j.psychres.2021.113853_bib0308","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"van Os","year":"2009","journal-title":"Schizophrenia. Lancet."},{"key":"10.1016\/j.psychres.2021.113853_bib0309","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Evolutionary perspectives on OCD","author":"van Schalkwyk","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0310","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0005-7967(01)00016-X","article-title":"Over-valued ideas: A conceptual analysis","volume":"40","author":"Veale","year":"2002","journal-title":"Behav. Res. Ther."},{"key":"10.1016\/j.psychres.2021.113853_bib0311","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1192\/apt.bp.107.004705","article-title":"Risk assessment in obsessive-compulsive disorder","volume":"15","author":"Veale","year":"2009","journal-title":"Adv. Psych. Treatment"},{"key":"10.1016\/j.psychres.2021.113853_bib0312","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1186\/s12888-014-0317-5","article-title":"Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis","volume":"14","author":"Veale","year":"2014","journal-title":"BMC. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0313","first-page":"38","article-title":"Outcomes for residential or inpatient intensive treatment of obsessive-compulsive disorder: A systematic review and meta-analysis","volume":"8","author":"Veale","year":"2016","journal-title":"J. OCD Rel Disord"},{"key":"10.1016\/j.psychres.2021.113853_bib0315","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.amjmed.2011.12.002","article-title":"Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?","volume":"125","author":"Vieweg","year":"2012","journal-title":"Am. J. Med."},{"key":"10.1016\/j.psychres.2021.113853_bib0316","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/070674379704200624","article-title":"A possible new treatment approach to obsessive-compulsive disorder","volume":"42","author":"Warneke","year":"1997","journal-title":"Can. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0317","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000445356","article-title":"Augmenting SRIs for obsessive-compulsive disorder: Patient preference for risperidone does not limit effectiveness of exposure and ritual prevention","volume":"85","author":"Wheaton","year":"2016","journal-title":"Psychother. Psychosomat."},{"key":"10.1016\/j.psychres.2021.113853_bib0318","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment.","first-page":"59","article-title":"Personality pathology in OCD: Comorbidity and contrast with OCPD and other personality disorders","author":"Wheaton","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0319","first-page":"1","article-title":"Autism spectrum disorders in adult outpatients with obsessive compulsive disorder in the UK","volume":"11","author":"Wikramanayake","year":"2018","journal-title":"Int. J. Psychiatry. Clin. Pract."},{"key":"10.1016\/j.psychres.2021.113853_bib0321","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10508-014-0421-0","article-title":"Domains of distress among people with sexual orientation obsessions","volume":"3","author":"Williams","year":"2015","journal-title":"Arch. Sex. Behav."},{"key":"10.1016\/j.psychres.2021.113853_bib0322","doi-asserted-by":"crossref","DOI":"10.1016\/j.brs.2021.10.428","article-title":"Accelerated neuromodulation therapy for obsessive-compulsive disorder","author":"Williams","year":"2021","journal-title":"Brain Stimul"},{"key":"10.1016\/j.psychres.2021.113853_bib0323","unstructured":"World Health Organization, 2018. International classification of diseases for mortality and morbidity statistics (11th revision). Retrieved from https:\/\/icd.who.int\/browse11\/l-m\/en, May 2020."},{"key":"10.1016\/j.psychres.2021.113853_bib0324","series-title":"Handbook of Autism and Anxiety","first-page":"107","article-title":"Obsessions, compulsions, and repetitive behavior: Autism and\/or OCD","author":"Wu","year":"2014"},{"key":"10.1016\/j.psychres.2021.113853_bib0325","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1176\/ajp.134.11.1298","article-title":"L-tryptophan in obsessive-compulsive disorders","volume":"134","author":"Yaryura-Tobias","year":"1977","journal-title":"Am. J. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0326","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1001\/archpsyc.1996.01830070103016","article-title":"Venlafaxine in obsessive-compulsive disorder","volume":"53","author":"Yaryura-Tobias","year":"1996","journal-title":"Arch. Gen. Psychiatry."},{"key":"10.1016\/j.psychres.2021.113853_bib0327","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WNF.0b013e31817f8cef","article-title":"High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: A case report with sustained full remission","volume":"32","author":"Yeh","year":"2009","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.psychres.2021.113853_bib0328","series-title":"Obsessive-Compulsive Disorder: Phenomenology, Pathophysiology, and Treatment","article-title":"Cognitive therapy for OCD","author":"Yule","year":"2017"},{"key":"10.1016\/j.psychres.2021.113853_bib0329","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2217\/pgs.14.83","article-title":"Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians","volume":"15","author":"Zai","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.psychres.2021.113853_bib0330","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.pnpbp.2018.12.009","article-title":"Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis","volume":"90","author":"Zhou","year":"2019","journal-title":"Prog. Neuropsychopharm. Biol. Psych."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121001505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178121001505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T05:51:28Z","timestamp":1759038688000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178121001505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":321,"alternative-id":["S0165178121001505"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2021.113853","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2021.113853","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113853"}}